Lagulao, Richel .
HRN: 21-76-72 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/19/2022
CEFUROXIME 500MG (TAB)
08/19/2022
08/26/2022
ORAL
500mg
Q12
Post NSVD With RMLE; Thickly MSAF
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes